ANI PHARMACEUTICALS, INC Restricted Cash and Cash Equivalents
ANI PHARMACEUTICALS, INC (ANIP) had Restricted Cash and Cash Equivalents of $5.01 million as of 2022-12-31, per its 10-K filed 2023-03-09.
Discontinued › Balance Sheet › Assets
us-gaap:RestrictedCashAndCashEquivalents · last filed 2023-03-09
- 2022-12-31: Restricted Cash and Cash Equivalents $5.01M.
- 2021-12-31: Restricted Cash and Cash Equivalents $5.00M.
- 2020-12-31: Restricted Cash and Cash Equivalents $5.00M.
- 2019-12-31: Restricted Cash and Cash Equivalents $5.03M.
| Period end | Restricted Cash and Cash Equivalents |
|---|---|
| 2022-12-31 | $5.01M 10-K · filed 2023-03-09 |
| 2021-12-31 | $5.00M 10-K · filed 2023-03-09 |
| 2020-12-31 | $5.00M 10-K · filed 2023-03-09 |
| 2019-12-31 | $5.03M 10-K · filed 2023-03-09 |
| 2013-09-30 | $2.26M 10-Q · filed 2013-11-07 |
| 2013-06-30 | $2.26M 10-Q · filed 2013-08-09 |
| 2013-03-31 | $2.26M 10-Q · filed 2013-05-10 |
| 2012-12-31 | $0.00 10-Q · filed 2013-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |